Basal cell carcinoma - Pipeline Insight, 2021
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Basal cell carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Basal cell carcinoma: Overview
Basal cell carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma. The main characteristics are: Slowly growing plaque or nodule, Skin colored, pink or pigmented, Varies in size from a few millimeters to several centimeters in diameter, Spontaneous bleeding or ulceration. Ultraviolet (UV) rays from the sun or from a tanning bed are the main cause of basal cell carcinoma. The goal of treatment for basal cell carcinoma is to remove the cancer completely. The clinical appearance, size, site, and histologic subtype determine choice of treatment: curettage and electrodesiccation, surgical excision, cryosurgery, topical chemotherapy (imiquimod or 5-fluorouracil) and photodynamic therapy, or, occasionally, radiation therapy. Large or recurrent basal cell cancers are treated best with Mohs' surgery (a specialized type of microscopically controlled surgery).
'Basal cell carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Basal cell carcinoma pipeline landscape is provided which includes the disease overview and Basal cell carcinoma treatment guidelines. The assessment part of the report embraces, in depth Basal cell carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Basal cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Basal cell carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Basal cell carcinoma Emerging Drugs
Further product details are provided in the report……..
Basal cell carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Basal cell carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Basal cell carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Basal cell carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal cell carcinoma drugs.
Basal cell carcinoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Basal cell carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Basal cell carcinoma: Overview
Basal cell carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma. The main characteristics are: Slowly growing plaque or nodule, Skin colored, pink or pigmented, Varies in size from a few millimeters to several centimeters in diameter, Spontaneous bleeding or ulceration. Ultraviolet (UV) rays from the sun or from a tanning bed are the main cause of basal cell carcinoma. The goal of treatment for basal cell carcinoma is to remove the cancer completely. The clinical appearance, size, site, and histologic subtype determine choice of treatment: curettage and electrodesiccation, surgical excision, cryosurgery, topical chemotherapy (imiquimod or 5-fluorouracil) and photodynamic therapy, or, occasionally, radiation therapy. Large or recurrent basal cell cancers are treated best with Mohs' surgery (a specialized type of microscopically controlled surgery).
'Basal cell carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Basal cell carcinoma pipeline landscape is provided which includes the disease overview and Basal cell carcinoma treatment guidelines. The assessment part of the report embraces, in depth Basal cell carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Basal cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Basal cell carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Basal cell carcinoma.
This segment of the Basal cell carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Basal cell carcinoma Emerging Drugs
- Patidegib: PellePharm
- AIV001: AiViva BioPharma
Further product details are provided in the report……..
Basal cell carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Basal cell carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Basal cell carcinoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Basal cell carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Basal cell carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal cell carcinoma drugs.
Basal cell carcinoma Report Insights
- Basal cell carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Basal cell carcinoma drugs?
- How many Basal cell carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Basal cell carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Basal cell carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Basal cell carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- PellePharm
- MedC Biopharma Corporation
- AiViva BioPharma
- MediWound
- Kintara Therapeutics
- IO Biotech
- Sirnaomics
- Aresus Pharma
- Epitome Pharmaceuticals
- Transgene
- Senhwa Biosciences
- Palvella Therapeutics
- Suzhou Kintor Pharmaceuticals
- Leaf Vertical
- AIV001
- Patidegib
- MDC-2060
- MWPC 005
- Rostaporfin
- IO103
- STP 705
- Polyphenon E
- AIV 001
- TG 1042
- Silmitasertib
- Sirolimus topical
- GT 1708F
- Cannabidiol
Introduction
Executive Summary
Basal cell carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Basal cell carcinoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Patidegib: PellePharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
IO103: IO Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
AIV001: AiViva BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Cannabidiol: Leaf Vertical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Basal cell carcinoma Key Companies
Basal cell carcinoma Key Products
Basal cell carcinoma- Unmet Needs
Basal cell carcinoma- Market Drivers and Barriers
Basal cell carcinoma- Future Perspectives and Conclusion
Basal cell carcinoma Analyst Views
Appendix
Executive Summary
Basal cell carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Basal cell carcinoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Patidegib: PellePharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
IO103: IO Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
AIV001: AiViva BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Cannabidiol: Leaf Vertical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Basal cell carcinoma Key Companies
Basal cell carcinoma Key Products
Basal cell carcinoma- Unmet Needs
Basal cell carcinoma- Market Drivers and Barriers
Basal cell carcinoma- Future Perspectives and Conclusion
Basal cell carcinoma Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Basal cell carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Basal cell carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Basal cell carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Basal cell carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products